Find Idronoxil manufacturers, exporters & distributors on PharmaCompass

Idronoxil

Idronoxil

Synopsis, Chemistry

DEVELOPMENTS

13 Drug(s) in Development

13 Drug(s) in Development

DIGITAL CONTENT

3 News

3 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Phenoxodiol, Dehydroequol, 81267-65-4, Haginin e, 3-(4-hydroxyphenyl)-2h-chromen-7-ol, 3-(4-hydroxyphenyl)-2h-1-benzopyran-7-ol

Molecular Formula

C₁₅H₁₂O₃

Molecular Weight

240.25 g/mol

InChI Key

ZZUBHVMHNVYXRR-UHFFFAOYSA-N

FDA UNII

995FT1W541

Idronoxil is a synthetic flavonoid derivative. Idronoxil activates the mitochondrial caspase system, inhibits X-linked inhibitor of apoptosis (XIAP), and disrupts FLICE inhibitory protein (FLIP) expression, resulting in tumor cell apoptosis. This agent also inhibits DNA topoisomerase II by stabilizing the cleavable complex, thereby preventing DNA replication and resulting in tumor cell death.

1 2D Structure

Idronoxil

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

3-(4-hydroxyphenyl)-2H-chromen-7-ol

2.1.2 InChI

InChI=1S/C15H12O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-8,16-17H,9H2

2.1.3 InChI Key

ZZUBHVMHNVYXRR-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1C(=CC2=C(O1)C=C(C=C2)O)C3=CC=C(C=C3)O

2.2 Other Identifiers

2.2.1 UNII

995FT1W541

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 7-hydroxy-3-hydroxyphenyl-1h-benzopyran

2. Phenoxodiol

2.3.2 Depositor-Supplied Synonyms

1. Phenoxodiol

2. Dehydroequol

3. 81267-65-4

4. Haginin E

5. 3-(4-hydroxyphenyl)-2h-chromen-7-ol

6. 3-(4-hydroxyphenyl)-2h-1-benzopyran-7-ol

7. Nv-06

8. 7,4'-dihydroxyisoflav-3-ene

9. 2h-1-benzopyran-7-ol, 3-(4-hydroxyphenyl)-

10. Idronoxil;dehydroequol;haginin E

11. 995ft1w541

12. Nv 06

13. Idronoxil [usan]

14. Ccris 8949

15. Idronoxil (usan/inn)

16. Idronoxil [usan:inn]

17. 7-hydroxy-3-hydroxyphenyl-1h-benzopyran

18. Haganin E

19. Unii-995ft1w541

20. Idronoxil [inn]

21. Phenoxodiol (haginin E)

22. Dehydroequol [mi]

23. Isoflav-3-ene4',7-diol

24. Idronoxil [who-dd]

25. Isoflav-3-ene-4',7-diol

26. Mls006010720

27. Schembl149612

28. 4',7-dihydroxyisoflav-3-ene

29. Chembl1957038

30. Phenoxodiol, >=98% (hplc)

31. Dtxsid50231029

32. ...7,4?-dihydroxyisoflav-3-ene

33. Nox-66 Component Idronoxil

34. Zinc1491943

35. Bdbm50419932

36. S9634

37. Akos015918005

38. Db04915

39. 3-(4-hydroxy-phenyl)-2h-chromen-7-ol

40. Ncgc00346822-01

41. Ncgc00346822-02

42. Hy-13721

43. Smr004701684

44. Xd161580

45. Xd161694

46. Db-012327

47. Cs-0007751

48. Ft-0602222

49. Nox66 Suppository Component Idronoxil

50. D04498

51. Idronoxil Component Of Nox66 Suppository

52. 267p654

53. A853212

54. Q27095562

55. (+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2h-cromen-7-ol

2.4 Create Date

2005-07-19

3 Chemical and Physical Properties

Molecular Formula	C₁₅H₁₂O₃
Molecular Weight	240.25 g/mol
XLogP3	2.7
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	1
Exact Mass	240.078644241 g/mol
Monoisotopic Mass	240.078644241 g/mol
Topological Polar Surface Area	49.7 Å²
Heavy Atom Count	18
Formal Charge	0
Complexity	318
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Intended for the treatment of various forms of cancer.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Phenoxodiol inhibits proliferation of many cancer cell lines and induces apoptosis by disrupting FLICE-inhibitory protein, FLIP, expression and by caspase-dependent and -independent degradation of the X-linked inhibitor of apoptosis, XIAP. In addition, phenoxodiol sensitizes drug-resistant tumour cells to anticancer drugs including paclitaxel, carboplatin and gemcitabine.

5.2 Mechanism of Action

The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Results from one study (PMID: 17904534) indicate that plasma membrane electron transport (PMET) may be a primary target for phenoxodiol in tumour cells and in activated T cells.